<DOC>
	<DOCNO>NCT02825563</DOCNO>
	<brief_summary>The purpose study study pharmacokinetic characteristic Anlotinib Advanced Cancer Patients High Fat Diet .</brief_summary>
	<brief_title>A Phase I Study Anlotinib Pharmacokinetics Assess Effect High Fat Diet Advanced Cancer Patients</brief_title>
	<detailed_description />
	<mesh_term>Neoplasms</mesh_term>
	<criteria>Histological documentation Advanced solid tumor ( Nonsmall Cell Lung Cancer.Soft Tissue SarcomaMedullary . Thyroid Carcinoma ) At least one measurable lesion ( RECIST1.1 ) Lack standard treatment treatment failure 20≤BMI≤25 1870 year , ECOG PS:01 , Life expectancy 3 month Main organ function normal Women childbearing potential agree use utilize adequate method contraception ( intrauterine device，contraceptive condom ) throughout treatment least 6 month study stopped；the result serum urine pregnancy test negative within 7 day prior study enrollment，and patient require nonlactating；Man participant agree use utilize adequate method contraception throughout treatment least 6 month study stop Patients participate study voluntarily sign informed consent Clear allergy study drug ingredient Had disease affect drug absorption metabolism Patients factor could affect oral medication ( dysphagia，chronic diarrhea , intestinal obstruction etc . ) Brain metastasis patient symptom symptom control &lt; 1 month Used drug inhibit induce hepatic drug metabolic enzymes 30 day study Patients drug abuse history unable get rid Patients mental disorder Patients participate anticancer drug clinical trial within 4 week Patients concomitant disease could seriously endanger safety could affect completion study accord investigator ' judgment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>July 2016</verification_date>
</DOC>